Bortezomib with HIG-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy

被引：0
|
作者：
Corso, Alessandro [1 ]
Barbarano, Luciana [2 ]
Mangiacavalli, Silvia [1 ]
Montalbetti, Luigi
Brasca, Paola [2 ]
Zappasodi, Patrizia [1 ]
Carella, Angelo [3 ]
Spriano, Mauro [3 ]
Alessandrino, Emilio Paolo [1 ]
Cairoli, Roberto [2 ]
Petro, Daniela [2 ]
Varettoni, Marzia [1 ]
Bernasconi, Paolo [1 ]
Lazzarino, Mario [1 ]
Morra, Enrica [2 ]
机构：
[1] Univ Pavia, Fdn IRCCS, Policlin San Matteo, Div Hematol, I-27100 Pavia, Italy
[2] Osped Ca Granda, Div Hematol, Milan, Italy
[3] Osped San Martino Genova, Div Hematol, Genoa, Italy
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3595
引用
收藏
页码：1051A / 1052A
页数：2
相关论文
共 50 条
  • [31] Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
    Kropff, M
    Bisping, G
    Liebisch, P
    Sezer, O
    Einsele, H
    Straka, C
    Kroeger, N
    Metzner, B
    Engelhardt, M
    Lang, N
    Hentrich, M
    Wolf, H
    von Schilling, C
    Salwender, H
    Berdel, WE
    Kienast, J
    BLOOD, 2005, 106 (11) : 716A - 716A
  • [32] Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant
    Mangiacavalli, Silvia
    Pochintesta, Lara
    Ravelli, Erika
    Baldini, Luca
    Ferretti, Virginia Valeria
    La Targia, Maria Luisa
    Farina, Lucia
    Cocito, Federica
    Cairoli, Roberto
    Montefusco, Vittorio
    Corso, Alessandro
    LEUKEMIA & LYMPHOMA, 2015, 56 (06) : 1901 - 1902
  • [33] High dose therapy in multiple myeloma
    Harousseau, JL
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2003, 187 (02): : 405 - 413
  • [34] Thalidomide/dexamethasone (TD), bortezomib (Velcade)/thalidomide/dexamethasone (VTD) and VBMCP/VBAD/Velcade as induction therapy prior to high-dose therapy/autologous stem cell transplantation in multiple myeloma
    Rosinol, L.
    Cibeira, M. T.
    Martinez, J.
    Mateos, M. V.
    Oriol, A.
    Terol, M. J.
    Garcia-Larana, J.
    Hernandez, D.
    de la Rubia, J.
    Sureda, A.
    Besalduch, J.
    Palomera, L.
    Gonzalez, Y.
    Echebeste, M. A.
    Diaz-Mediavilla, J.
    de Arriba, F.
    Alegre, A.
    Hernandez, M.
    Lahuerta, J. J.
    Miguel, J. F. San
    Blade, J.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S18 - S18
  • [35] Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy
    Corso, A.
    Mangiacavalli, S.
    Barbarano, L.
    Montalbetti, L.
    Mazzone, A.
    Fava, S.
    Varettoni, M.
    Zappasodi, P.
    Morra, E.
    Lazzarino, M.
    LEUKEMIA RESEARCH, 2008, 32 (07) : 1085 - 1090
  • [36] Bortezomib-pegylated liposomal doxorubicin-dexamethasone as a primary therapy in newly diagnosed multiple myeloma patients before high-dose melphalan with PBSC transplantation
    Pitini, V
    Altavilla, G
    Arrigo, C
    Naro, C
    Siracusano, L
    Sciarrone, P
    BONE MARROW TRANSPLANTATION, 2006, 37 : S142 - S142
  • [37] The role of thalidomide in myeloma patients eligible for high-dose therapy
    Cavo, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 28 - 29
  • [38] Is there still place for high-dose therapy in the elderly myeloma patients?
    Palumbo, A.
    Bringhen, S.
    Gay, F.
    Magarotto, V.
    Corso, A.
    Offidani, M.
    Musto, P.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 49 - 50
  • [39] Nursing challenges for treating relapsed multiple myeloma with bortezomib (velcade) compared with high-dose dexamethasone.
    Kelly-Colson, K
    ONCOLOGY NURSING FORUM, 2005, 32 (02) : 471 - 471
  • [40] HIGH-DOSE DEXAMETHASONE FOR REFRACTORY OR RELAPSING MULTIPLE-MYELOMA
    FRIEDENBERG, WR
    KYLE, RA
    KNOSPE, WH
    BENNETT, JM
    TSIATIS, AA
    OKEN, MM
    AMERICAN JOURNAL OF HEMATOLOGY, 1991, 36 (03) : 171 - 175
12345